263 related articles for article (PubMed ID: 17855727)
21. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity.
Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
J Pharm Pharmacol; 2005 Oct; 57(10):1289-95. PubMed ID: 16259757
[TBL] [Abstract][Full Text] [Related]
22. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.
Graybill JR; Kaster SR
Am Rev Respir Dis; 1984 Feb; 129(2):292-5. PubMed ID: 6364905
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic efficacy of posaconazole in a murine model of disseminated trichosporonosis.
Treviño-Rangel Rde J; López LJ; Palma-Nicolás JP; Hernández-Bello R; González JG; González GM
J Antimicrob Chemother; 2014 Apr; 69(4):1075-8. PubMed ID: 24252752
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of posaconazole in a murine model of disseminated infection caused by Apophysomyces variabilis.
Salas V; Pastor FJ; Calvo E; Sutton DA; Chander J; Mayayo E; Alvarez E; Guarro J
J Antimicrob Chemother; 2012 Jul; 67(7):1712-5. PubMed ID: 22427614
[TBL] [Abstract][Full Text] [Related]
25. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
26. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
[TBL] [Abstract][Full Text] [Related]
27. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
28. [A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis].
Yang X; Dong XG; Liu AM; Sun SY; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2007 Jun; 43(6):546-53. PubMed ID: 17897534
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
30. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
31. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
[TBL] [Abstract][Full Text] [Related]
32. Role of inhaled amphotericin in allergic bronchopulmonary aspergillosis.
Sehgal IS; Agarwal R
J Postgrad Med; 2014; 60(1):41-5. PubMed ID: 24625938
[TBL] [Abstract][Full Text] [Related]
33. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
34. In Vitro and In Vivo Efficacy of Amphotericin B Combined with Posaconazole against Experimental Disseminated Sporotrichosis.
Mario DN; Guarro J; Santurio JM; Alves SH; Capilla J
Antimicrob Agents Chemother; 2015 Aug; 59(8):5018-21. PubMed ID: 26014930
[TBL] [Abstract][Full Text] [Related]
35. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis.
Hayes D; Murphy BS; Lynch JE; Feola DJ
Pediatr Pulmonol; 2010 Nov; 45(11):1145-8. PubMed ID: 20658484
[TBL] [Abstract][Full Text] [Related]
36. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.
Lionakis MS; Lewis RE; Chamilos G; Kontoyiannis DP
Pharmacotherapy; 2005 Sep; 25(9):1174-80. PubMed ID: 16164392
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
38. Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis.
Becker MJ; de Marie S; Fens MH; Verbrugh HA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2003 Sep; 52(3):428-34. PubMed ID: 12917249
[TBL] [Abstract][Full Text] [Related]
39. Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration.
Chryssanthou E; Sjölin J
J Antimicrob Chemother; 2004 Nov; 54(5):940-3. PubMed ID: 15471994
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
Clemons KV; Parmar R; Martinez M; Stevens DA
J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
